Literature DB >> 30775031

Update on emerging biomarkers in lung cancer.

Eric H Bernicker1, Timothy Craig Allen2, Phillip T Cagle3.   

Abstract

There has been considerable progress made in identifying oncogenic driver mutations in advanced lung cancer. The recognition that lung cancer is actually an umbrella classification that is comprised of multiple molecular subgroups has had a profound impact on how medical oncologists make treatment decisions. These mutations are clinically important as available targeted therapies can achieve significant responses and prolonged disease control. This review will summarize the current guidelines for biomarker testing and available therapeutic agents.

Entities:  

Keywords:  BRAF; Biomarkers; MET; RET; anaplastic lymphoma kinase (ALK); epidermal growth factor receptor (EGFR); tumor mutational burden

Year:  2019        PMID： 30775031      PMCID： PMC6353743          DOI： 10.21037/jtd.2019.01.46

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


  8 in total

Review 1.  Independent Drug Action in Combination Therapy: Implications for Precision Oncology.

Authors:  Deborah Plana; Adam C Palmer; Peter K Sorger
Journal:  Cancer Discov       Date:  2022-03-01       Impact factor: 38.272

2.  NEIL3 Mediates Lung Cancer Progression and Modulates PI3K/AKT/mTOR Signaling: A Potential Therapeutic Target.

Authors:  Hongbo Huang; Qingwang Hua
Journal:  Int J Genomics       Date:  2022-04-30       Impact factor: 2.758

Review 3.  The multifaceted anti-cancer effects of BRAF-inhibitors.

Authors:  Laura Croce; Francesca Coperchini; Flavia Magri; Luca Chiovato; Mario Rotondi
Journal:  Oncotarget       Date:  2019-11-12

4.  Identification of transcriptional subtypes in lung adenocarcinoma and squamous cell carcinoma through integrative analysis of microarray and RNA sequencing data.

Authors:  François Fauteux; Anuradha Surendra; Scott McComb; Youlian Pan; Jennifer J Hill
Journal:  Sci Rep       Date:  2021-04-22       Impact factor: 4.996

5.  Retrospective analysis of real-world treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer starting first-line systemic therapy in the United Kingdom.

Authors:  Jason Lester; Carles Escriu; Sarah Khan; Emma Hudson; Talal Mansy; Andrew Conn; Samuel Chan; Ceri Powell; Juliet Brock; John Conibear; Lauren Nelless; Vaneet Nayar; Xiaohui Zhuo; Adeline Durand; Amerah Amin; Peter Martin; Xinke Zhang; Vivek Pawar
Journal:  BMC Cancer       Date:  2021-05-07       Impact factor: 4.430

6.  circPTN Promotes the Progression of Non-Small Cell Lung Cancer through Upregulation of E2F2 by Sponging miR-432-5p.

Authors:  Jiayuan Su; Jinrong Zhou; Yachan Feng; Haojie Zhang; Xinyu Zhang; Xiaorong Zhao; Yong Li; Xueling Guo
Journal:  Int J Genomics       Date:  2022-09-20       Impact factor: 2.758

7.  In silico assessment of EpCAM transcriptional expression and determination of the prognostic biomarker for human lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC).

Authors:  Abu Tayab Moin; Bishajit Sarkar; Md Asad Ullah; Yusha Araf; Nafisa Ahmed; Bashudev Rudra
Journal:  Biochem Biophys Rep       Date:  2021-07-19

8.  Absence of Nuclear p16 Is a Diagnostic and Independent Prognostic Biomarker in Squamous Cell Carcinoma of the Cervix.

Authors:  Saioa Mendaza; Joaquín Fernández-Irigoyen; Enrique Santamaría; Tamara Zudaire; Rosa Guarch; David Guerrero-Setas; August Vidal; José Santos-Salas; Xavier Matias-Guiu; Karina Ausín; María José Díaz de Cerio; Esperanza Martín-Sánchez
Journal:  Int J Mol Sci       Date:  2020-03-19       Impact factor: 6.208
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.